Keep up to date with the latest findings in therapy for hepatocellular carcinoma (HCC) from the 2017 annual liver cancer conference in Seoul. This online activity provides an overview of key data from the conference, as well as how these findings fit into the current and evolving standard of care for advanced liver cancer.
0.5 AMA PRA Category 1 Credits™
Sep 19, 2017
Sep 19, 2018
Abstract #O-031: Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
Abstract #P-008: Integrated safety analysis from four phase 3 trials of regorafenib (Reg)
Abstract #P-036: Integrated safety analysis from seven sorafenib (SOR) trials in patients with hepatocellular carcinoma
Abstract #P-034: Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS, an international observational study assessing the use of sorafenib after TACE
Abstract #P-056: Weak correlation of overall survival (OS) and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC)
Abstract #O-030: Nivolumab in sorafenib-naïve and -experienced patients with advanced hepatocellular carcinoma: CheckMate 040 study
Abstract #O-001: Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients with unresectable hepatocellular carcinoma (UHCC)
Jordi Bruix, MD, PhDUniversity of Barcelona
Peter R. Galle, MD, PhDUniversity Medical Center Mainz
After successful completion of this educational activity, participants should be able to:
- Evaluate emerging clinical trial data in HCC, including studies focused on the safety and efficacy of novel targeted therapies
- Select patients who may benefit from emerging therapies in HCC
This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Dr Bruix has disclosed that he has received consulting fees from Abbott, Arqule, Bayer, Bristol-Myers Squibb, BTG, Daichi, GlaxoSmithKline, Kowa, Lilly, Novartis, and Roche. He has also received honoraria for promotional speaker’s bureaus and has received fees for speaking and teaching from Bayer, BTG, and Sirtex. Furthermore, he worked as an independent contractor for Arqule, Bayer, and Daichi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Galle has disclosed that he has received consultation fees from AstraZeneca, Bayer, BMS, MSD, Lilly, Sillajen, and Sirtex. He also performed contracted research for Bayer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Zach Hartman, PhD (scientific content reviewer/planner) – Ownership interest in Advaxis, Inc
- Christi Gray (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.